Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.

ABSTRACT:

Aims

Obesity adversely affects atrial fibrillation (AF) outcomes and is associated with higher recurrence after catheter ablation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve metabolic inflammation, but their role as adjuncts to ablation has not been completely defined. This study investigated the impact of semaglutide on post-ablation rhythm outcomes in obese patients with AF.

Methods and results

This single-centre, propensity-matched study included obese patients [body mass index (BMI) ≥ 30 kg/m²] undergoing first-time catheter ablation for paroxysmal AF (2019-2024). Patients who initiated semaglutide within 3 months before or 1 month after ablation were compared with matched controls who did not receive GLP-1RA therapy. All patient

SUBMITTER: Ciconte G 

PROVIDER: S-EPMC12910615 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature